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Endothelial cells are involved in the pathogenesis of acute graft-versus-host disease (GVHD) after allogeneic stem cell
transplantation. These cells express several molecules that can be detected as biologically active soluble forms; serum levels of
these molecules may thereby reflect the functional status of endothelial cells. Furthermore, acute GVHD is an inflammatory
reaction and endothelial cells function as local regulators of inflammation. We therefore investigated whether differences in
preconditioning/pretransplant serum levels of endothelium-expressed molecules (i.e., endocan, vascular cell adhesion molecule
1 (VCAM-1), and E-selectin) were associated with a risk of posttransplant GVHD. Our study should be regarded as a population-
based study of consecutive and thereby unselected patients (𝑛 = 56). Analysis of this pretreatment endothelium biomarker profile
by unsupervised hierarchical clustering identified a subset of patients with increased early nonrelapse mortality. Furthermore, low
endocan levels were significantly associated with acute GVHD in the liver and gastrointestinal tract, whereas high VCAM-1 levels
were associated with acute GVHD in the skin only. Our study suggests that the preconditioning/pretransplant status of endothelial
cells (possibly through altered trafficking of immunocompetent cells) is important for the risk and the organ involvement of later
acute GVHD.
1. Introduction
Allogeneic hematopoietic stem cell transplantation has a
strong antileukemic effect [1, 2] but is also associated with a
relatively high risk of serious posttransplant complications,
for example, graft-versus-host disease (GVHD) [3]. Endothe-
lial cells and endothelial cell damage seem to be involved
in the development of several posttransplant complications,
including GVHD [4–6]. Furthermore, endothelial cell adhe-
sion molecules are highly expressed after allotransplantation
especially in GVHD-affected tissue, and soluble E-selectin
(CD62E) serum levels are increased during acute GVHD
whereas levels of intercellular adhesion molecule-1 (ICAM-
1) and vascular cell adhesion molecule 1 (VCAM-1) are only
increased in chronic GVHD [6–8]. Levels of circulating
endothelial cells can also be a marker of conditioning-
induced endothelial damage [9, 10]. All these observations
are consistent with the hypothesis that endothelial cells are
important in GVHD development. Finally, endocan is a
proteoglycan expressed by endothelial cells; a soluble form is
detected in serum [11] and the serum levels can be altered by
infections, trauma, andmalignancies as well as nonmalignant
disorders [12–18]. The levels are also altered by antileuke-
mic chemotherapy [12, 13], but serum endocan levels in
allotransplant recipients have not been investigated.
Previous studies have demonstrated that the precondi-
tioning/pretransplant clinical status is important for the risk
of developing severe posttransplant complications [19, 20],
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and we therefore investigated whether the pretransplant
serum levels of endocan as well as soluble adhesionmolecules
derived from endothelial cells (E-selectin and VCAM-1) are
associated with the development of posttransplant acute
GVHD. In contrast to the previous studies mentioned above
we did not investigate the possible diagnostic or prognostic
use of endothelial biomarkers during GVHD; we examined
the possible associations between pretreatment levels and
development of posttransplant complications. The three
biomarkers were selected for our study because (i) they
either are endothelial-specific (E-selectin and endocan) or
are expressed only by a limited number of cells and mainly
immunocompetent cells in addition to the endothelial cells
(VCAM-1) and (ii) all three are important for leukocyte
migration across the vessel wall and may therefore be
involved in the pathogenesis of acute GVHD [21, 22].
2. Methods
2.1. Patients andHealthy Controls. The studies were approved
by the Regional Ethics Committee III, University of Bergen,
Norway. Samples were collected after written informed con-
sent. The study included 56 consecutive allotransplanted
patients (Table 1) during a 77-month period, representing all
adult patients from a defined geographic area (Norwegian
Health Regions III, IV, and V) transplanted with a family
donor; the decision to do an allotransplantation was taken by
theNorwegianAdvisory Board for StemCell Transplantation
and based on national guidelines. Thus, our study should be
regarded as a population-based study including an unselected
consecutive group of well-characterized patients (Table 1).
All patients were carefully examined for and classified with
regard to comorbidity according to Sorror et al. [23]; none of
the patients had liver or renal disease and the overall comor-
bidity score was very low (1 or 0). All except three patients
were Caucasians; they all received GVHD prophylaxis with
cyclosporin A plus methotrexate and all except two aplastic
anemia patients were transplanted with granulocyte colony-
stimulating factor (G-CSF) mobilized peripheral blood stem
cells. Sinusoidal obstruction syndrome was not diagnosed in
any patient. Neutrophil reconstitution was defined as three
consecutive days with neutrophil counts of ≥0.2/0.5 × 109/L
and platelet reconstitution as platelet counts ≥20/50 × 109/L
for at least 3 consecutive days. Capillary leak syndrome was
defined as at least 10% weight gain during 24 hours despite
diuretic therapy. All samples were collected before start of
conditioning therapy (median 19 days before, range 3–56
days).
GVHD was diagnosed according to generally accepted
criteria [24, 25]. Briefly, the diagnosis of acute GVHD was
generally based on careful clinical evaluation and additional
skin biopsies for patients with skin involvement alone. The
diagnosis of acute GVHD for the patients with liver and/or
gastrointestinal involvement was also based on careful clini-
cal evaluation and additional biopsies (including 8 with skin
biopsies and 5 with biopsies from the gastrointestinal tract)
except for one patient with liver involvement where acute
GVHD was a clinical diagnosis.
Table 1: Clinical and biological characteristics of allotransplanted
patients included in the study.











Myelofibrosis secondary to polycythemia vera 1
Aplastic anemia 2
Status at the time of transplantation
First complete hematological remission 41
Second or later complete remission 8
Previous allogeneic stem cell transplantation and
now complete remission 1
Detectable disease 6
Conditioning therapy
Busulfan + cyclophosphamide 52
Total body irradiation + cyclophosphamide 1
Antithymocyte globulin + cyclophosphamide 2
BEAM (carmustine, etoposide, cytarabine, and
melphalan) 1
Stem cell grafts
Peripheral blood mobilized stem cells 54
Bone marrow 2
GVHD prophylaxis with cyclosporin A plus
methotrexate
4 methotrexate injections 34
3 methotrexate injections 21
2 methotrexate injections 1








The controls included 19 Caucasians (median age 42
years, range 23–57 years; 10 females and 9 males).
2.2. Analysis of Serum Adhesion Molecule Levels. Venous
blood was collected (BD Vacutainer SST Serum Separation
Tubes, Becton-Dickenson; Franklin Lakes, NJ, USA) and
allowed to coagulate for 120 minutes at room temperature
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Figure 1: Serum levels of soluble adhesion molecules derived from endothelial cells (endocan, E-selectin, and VCAM-1) in healthy controls
(healthy) and in consecutive/unselected patients prior to pretransplant conditioning therapy and allogeneic stem cell transplantation. A total
of 56 patients were studied (endocan), but VCAM and E-selectin levels were available only for 50 consecutive/unselected patients.
before centrifugation (1300 g for 10 minutes) and serum
collection. Serum was immediately frozen and stored at
−80∘C until analyzed. Average storage time for patients was
30 months and for controls 25 months. Endocan levels were
determined by ELISA analyses (Lunginnov, Pasteur Institute,
Lille, France). E-selectin (CD62E) and VCAM-1 were ana-
lyzed by Luminex analyses (R&D Systems; Abingdon, UK).
All analyses were performed in duplicate strictly according
to the manufacturers’ instructions. Due to technical reasons
VCAM-1 and E-selectin were analyzed only for 50 consecu-
tive/unselected patients.
2.3. Statistical and Bioinformatical Analyses. Bioinformatical
analyses were performed using the J-Express (MolMine AS;
Bergen, Norway) [26]. For hierarchical clustering all values
were median variance standardized and log(2) transformed.
The complete linkage was used as linkage method, and
for distance measured the Euclidean correlation was used.
Additional statistical analyses were performed using the
Statistical Package for the Social Sciences version 15.0 (SPSS
Inc., Chicago, IL, USA) and GraphPad Prism 4 (Graph Pad
Software, Inc., San Diego, CA, USA). Pearson correlation
for bivariate samples was used for correlation analyses and
the Mann-Whitney 𝑈 test and chi-square test were used
to compare different groups. Differences were regarded as
statistically significant when 𝑃 values < 0.05.
3. Results
3.1. Pretransplant Serum Levels of Endothelium-Derived Adhe-
sion Molecules Show a Wide Variation. We compared the
preconditioning/pretransplant serum endocan levels for 56
consecutive patients with the levels of 19 healthy controls
(Figure 1); the endocan levels did not differ significantly
whereas the patients showed significantly decreased sE-
selectin (Mann-Whitney 𝑈 test, 𝑛 = 50, 𝑃 = 0.0023) and
increased sVCAM-1 levels (𝑛 = 50, 𝑃 = 0.012). Further-
more, all acute leukemia patients had undergone intensive
chemotherapy and had normal bone marrow blast counts at
the time of pretransplant sampling, but the hematological
reconstitution varied. Six patients had peripheral blood
neutrophil counts below 1 × 109/L. With regard to platelet
reconstitution 6 patients had pretransplant peripheral blood
platelets <100 × 109/L, 14 patients had 100–140 × 109/L, 31
patients had normal counts, and 5 patients had precondition-
ing/pretransplant counts above the upper normal limit.
3.2. The Preconditioning Serum Profile of Endothelium-De-
rived Molecules Identifies a Patient Subset with Increased Fre-
quency of Acute GVHD. We investigated the possible asso-
ciation between the preconditioning endothelial biomarker
profile and acute GVHD by using unsupervised hierarchical
clustering analysis and including 50 consecutive/unselected
patients (Figure 2). Twomain patient subsets were identified:
one including 23 patients (the right subset in Figure 2)
and the other including 27 patients. VCAM-1 was the only
biomarker that differed significantly between these two sub-
sets (Table 2; Mann-Whitney 𝑈 test, 𝑃 = 0.0048). Thus,
serum VCAM-1 levels have a major impact on the iden-
tification of these two patient subsets. Furthermore, acute
GVHD was observed in 12 of the 23 patients in the right
subset but only for three of the 27 patients in the left subset
(Figure 2, chi-square test, 𝑃 = 0.0016). Our analysis also
identified a small subset, that is, the 10 patients in the outer left










Figure 2: Differences in the serum profile of soluble adhesion molecules derived from endothelial cells (endocan, E-selectin, and VCAM-1)
are associated with the frequency of posttransplant acute GVHD. Serum levels of all three endothelium-derived soluble adhesion molecules
were determined for 50 consecutive/unselected patients (only those patients where the levels of all three mediators were available) prior to
pretransplant conditioning therapy. An unsupervised hierarchical cluster analysis was performed and two major patient subsets were then
identified, that is, the right 23 and the left 27 patients.The observation of acute GVHD is indicated in the right part of the figure; green squares
indicate skin GVHD alone and red squares indicate that the patients had gastrointestinal or liver affection eventually in combination with
skin GVHD. Early (i.e., within 4 weeks of posttransplant) nonrelapse death due to multiorgan failure (MOF) or early acute GVHD grade 4
with later death due to multiorgan failure is also indicated in the figure.
Table 2: Unsupervised hierarchical clustering of serum soluble adhesion levels for 50 unselected patients treated with allogeneic stem cell
transplantation; a comparison of the two main patient subsets including the 23 patients to the right and the 27 patients to the left in Figure 2,
respectively.
Adhesion molecule—clinical parameter Left patient subset, 𝑛 = 27 Right patient subset, 𝑛 = 23 𝑃 value
Endocan (ng/mL) 1.567 (0.908–2.452) 0.893 (0.148–2.901) 0.0516
VCAM-1 (ng/mL) 691.6 (317.3–1130.0) 1410 (300.0–5816.4) 0.0048
E-selectin (ng/mL) 25.4 (9.0–54.8) 21.7 (12.9–104.1) 0.4595
Frequency of early nonrelapse death 2/27 8/23 0.007
Time to neutrophils ≥0.2 × 109/L 14.5 days (11–19 days) 15 days (10–26 days) ns
Time to neutrophils >0.5 × 09/L 16 days (11–24 days) 18 days (12–28 days) 0.052
Time to platelets >20 × 109/L 12 days (9–>22 days) 16 days (12–30 days) 0.032
Time to platelets >50 × 109/L 16 days (12–38 days) 25 days (13–>71 days) 0.028
TheMann-Whitney𝑈 test was used for statistical analyses. Results are presented as themedian value and the variation range. Patients who died before reaching
platelet reconstitution were not included in the statistical comparison of time until reconstitution (ns: not significant).
cluster, without acute GVHD. Finally, the right main cluster
showed an increased overall frequency of early death due
to multiorgan failure (Figure 2, chi-square test, 𝑃 = 0.007).
There was also a difference in platelet reconstitution between
these two main subsets with regard to time until peripheral
blood platelet count >20 × 109/L (Table 2, 𝑃 = 0.032) and
>50 × 109/L (𝑃 = 0.028), whereas there was only a trend for
different time until neutrophils >0.5 × 109/L (𝑃 = 0.052).
The two main clusters identified in Figure 2 did not
differ with regard to age, gender distribution, diagnosis,
disease stage, organ affection or severity of acute GVHD, and
maximal weight gain during the first four weeks after start of
conditioning therapy (data not shown). Thirty-six of the 50
patients included in the cluster analysis were followed for at
least 1 year after transplantation. There was a significant dif-
ference in survival between these twomain subsets (Figure 3),
but the two clusters showed no significant difference in the
frequencies of chronic GVHD and leukemia relapse (data not
shown).
3.3. Patients with Acute GVHD of the Liver and Gastrointesti-
nal Tract Show Low Serum Endocan Levels. Serum endocan
levels prior to conditioning treatment were determined for 56
consecutive patients and showed a wide variation (Figure 1;
median 1.57 ng/mL, range 0.15–2.91 ng/mL) without any
significant associations with age, gender, diagnosis, relapse
versus first diagnosis, or peripheral blood platelet count at the
time of sampling (data not shown).
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Figure 3:The association between serum adhesionmolecule profile
and survival. The serum profile of endothelium-derived soluble
adhesion molecules identifies two major patient subsets that differ
in survival. Based on the analysis presented in Figure 2 we identified
two main patient clusters. We did a Kaplan-Mayer analysis to
compare the survival between these two subsets, and a significant
differencewas then detected between the two groups.This difference
was caused by nonrelapse mortality.
We then compared patients with preconditioning serum
levels above and below the median level of 1.57 ng/mL.
The overall frequency and severity of acute GVHD did not
differ between these two groups, but all seven patients with
acute GVHD affecting the liver and/or gastrointestinal tract
showed serum endocan concentrations below the median
level (Figure 4). Thus, there is a statistically significant asso-
ciation between low preconditioning/pretransplant serum
endocan levels and later organ involvement in acute GVHD.
This difference was statistically significant when comparing
the liver/gastrointestinal GVHD patients both with all other
patients (Mann-Whitney 𝑈 test, 𝑃 = 0.004) and with the
subset of patients without GVHD (Figure 4, 𝑃 = 0.009). The
maximal weight variation during the first 4 weeks after start
of conditioning did not differ between patients with serum
endocan levels above (median weight variation 5.5 kg, varia-
tion range −6 to 18 kg) and below (median 5.6 kg, range −6
to 20 kg) the median level. Preconditioning serum endocan
levels showed no correlation with (i) the corresponding levels
of VCAM-1 (𝑃 = 0.43) and E-selectin (𝑃 = 0.28) or (ii) time
until neutrophil/platelet reconstitution (data not shown).
A consecutive subset of 42 patients were observed for
at least 12 months after stem cell transplantation; for these
patients preconditioning serum endocan levels showed no
association with the later development of chronic GVHD
(data not shown).
3.4. Patients with Acute GVHD Only Affecting the Skin Show
High SerumVCAM-1 prior toTherapy. SerumVCAM-1 levels
were determined before start of conditioning therapy for 50
unselected patients. We observed skin GVHD alone in 9
patients and 8 of them showed serum VCAM-1 levels higher
than the median level for all 50 patients (Figure 4). This
difference was statistically significant both when comparing
the skin-alone GVHDpatients with all other patients (Mann-
Whitney 𝑈 test, 𝑃 = 0.011) and when comparing them
with the subset of patients without GVHD (Figure 4, 𝑃 =
0.019). In contrast, serum VCAM-1 levels did not show
any associations with the frequency of gastrointestinal and
liver GVHD, time until neutrophil/platelet reconstitution, or
maximal weight variation during the first 4 weeks after start
of conditioning therapy.The preconditioning serum VCAM-
1 and E-selectin levels showed no significant correlation
(𝑃 = 0.45). Finally, a consecutive subset of 36 patients were
observed at least 12 months after stem cell transplantation;
for these patients the preconditioning serum VCAM-1 level
showed no association with the development of chronic
GVHD (data not shown).
3.5. Serum E-Selectin Levels before Start of ConditioningTher-
apy ShowNo Significant Associations with Later Acute GVHD.
Preconditioning serum E-selectin levels showed a wide
variation (Figures 1 and 4) with no associations with fre-
quency, severity, or organ affection of acute GVHD. There
was a borderline inverse correlation between precondition-
ing/pretransplant E-selectin level and time until neutrophils
>0.2 × 109/L (𝑃 = 0.051); this association reached statistical
significance for time until neutrophils >0.5 × 109/L (𝑃 =
0.037). Finally, we did not observe any correlation between
the serum E-selectin levels and time until platelet recovery or
maximal weight variation during the first 4 weeks after start
of conditioning therapy (data not shown).
4. Discussion
Few previous studies have investigated the possible impor-
tance of preconditioning/pretransplant serum mediator lev-
els as prognostic biomarkers in allogeneic stem cell trans-
plantation; previous studies have mainly focused on single
endothelial biomarkers as diagnostic or prognostic tools in
patients with manifest acute GVHD rather than the possible
use or biomarker profiles in the pretransplant evaluation
of allotransplant recipients. Endothelial cells are important
regulators of immunocompetent cell trafficking, and soluble
forms of endothelium-derived molecules may thereby alter
cell trafficking or reflect the functional status of endothelial
cells [9, 10, 27]. Our results suggest that even the endothelial
cell status prior to conditioning is important for the risk of
acute GVHD.
The current treatment of acute GVHD is based on general
immunosuppression [28]. However, therapeutic targeting of
immunocompetent cell trafficking by blocking the CCR5
chemokine receptor has also been tried, and patients receiv-
ing this prophylaxis only had skin but not gut or liver GVHD
[29]. These results together with our present observations
are thus consistent with the hypothesis that organ-dependent
differences in endothelial cell phenotype influence the organ
involvement in acute GVHD [30].
Pretransplant characteristics are important for the risk of
posttransplant acute GVHD, for example, advanced disease,
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Figure 4: Differences in the serum profile of soluble adhesion molecules derived from endothelial cells (endocan, E-selectin, and VCAM-1)
are associated with posttransplant acute GVHD. Serum levels of endothelium-derived soluble adhesionmolecules were compared for patients
without acute GVHD, patients with skin GVHD alone, and patients with liver and/or gastrointestinal affection during acute GVHD. Serum
levels of endocan were available for all 56 patients (11 with acute GVHD in the skin and 7 with liver/gut involvement); for VCAM-1 and
E-selectin serum levels were available only for 50 consecutive/unselected patients (9 with acute GVHD in the skin only and 6 with liver/gut
involvement). The statistically significant differences (Mann-Whitney 𝑈 test) are indicated in the figure.
the conditioning regimens, and previous viral infections
[20, 31], and even differences in the pretransplant serum
cytokine profile seem to be associated with the risk of GVHD
[19]. The serum levels of soluble adhesion molecules derived
from endothelial cells may serve as additional markers of
endothelial damage or functional status [6, 7, 32–34]. Several
other soluble mediators have been examined previously, for
example, thrombomodulin and von Willebrand factor [9],
but as discussed in detail previously [9] they have several
limitations and their systemic levels depend on various
host factors including renal function, pharmacotherapy, liver
disease, viral infections, or other diseases like hypertension
and diabetes. In this context we studied the precondi-
tioning/pretransplant serum profile of endothelium-derived
soluble molecule for a population-based, well-characterized,
and consecutive group of recipients.
Few previous studies have investigated associations be-
tween pretransplant biomarker levels and the posttransplant
clinical course after allotransplantation [26, 32–34]. Firstly,
the risk of serious complications early after allotransplan-
tation is associated with the preconditioning serum profile
of immunoregulatory and angioregulatory mediators [19].
Secondly, an association between serum levels of angioreg-
ulatory angiopoietin-2/Tie2, and relapse-free survival was
described for a selected group of high-risk patients with
only 17 out of 90 patients being in complete remission
prior to transplantation [35, 36]. These patients are thus not
comparable to our unselected patients. Thirdly, in a pediatric
study Porkholm et al. [37] described that pretransplant high
angiopoietin-2 plasma levels were associated with increased
risk of gastrointestinal GVHD and nonrelapse mortality, but
in contrast to our study these authors examined the levels
at day 0 after conditioning. Finally, endocan and soluble
adhesion molecules were not examined in previous studies
that focused on endothelialmarkers as prognostic parameters
with regard to GVHD response to steroid treatment, and
these authors did not detect any differences in pretransplant
biomarkers between patients with or without later acute
GVHD [35–37]. Thus, our present study is the only one to
suggest an association between the endothelial cell status
prior to conditioning therapy and risk of later acute GVHD.
Our serum samples were prepared by a standardized
procedure and the measured biomarker levels will include
the levels of biologically active free molecules that are
released after proteolysis or by secretion [7, 32, 33]. However,
we cannot exclude the possibility that endothelium-derived
microparticles are present in our samples and contribute
to the measured biomarker levels. Microparticles can be
removed by ultracentrifugation [38, 39], that is, a method
usually not available at routine clinical laboratories. Our
intention was to investigate biomarker levels in samples that
can be prepared as a part of routine clinical evaluation of
these patients [7], and for that reasonwe used standard serum
samples.
Gastrointestinal and liver GVHD were associated with
low endocan levels whereas acute GVHD only involving the
skin showed increased VCAM-1 levels (Figure 4); a possi-
ble explanation for this is organ-dependent differences of
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the endothelial cell phenotype for the involved organs. Pro-
teomic studies have clearly demonstrated that the endothe-
lial cell phenotype differs between organs; this is probably
because the tissue microenvironment surrounding the blood
vessels controls the phenotype [40, 41]. This influence of
the microenvironment has also been documented in exper-
imental studies [42], and the differences are so extensive that
vascular targeting is even considered for directing anticancer
drugs to defined compartments or organs [43]. Only a minor
part of this proteomic heterogeneity has been characterized
in detail at a molecular level, but the endothelial pheno-
type characterized by phage display techniques differs, for
example, between skin and intestine [42] and between large
blood vessels and microvessels [44]. The microenvironment-
dependent variation in endothelial cell phenotype can also
explain the differences in endothelium-derived biomarker
levels with regard to organs involved in acute GVHD. Organ-
specific variations, differences between microvessels and
large vessels, and different effects on the vessel-surrounding
microenvironment by various parenchymal disorders may
also explain why endothelial biomarker levels in acute liver
GVHD (normal VCAM-1) differ from other liver diseases,
for example, cirrhosis with increased hepatic vein pressure
gradients showing increased systemic VCAM-1 levels [45].
Endothelial cells contribute to the formation of vascular
stem cell niches [46–48] and they are also important regula-
tors of fluid transport across the vessel wall [49, 50]. How-
ever, the serum levels of endothelium-derived biomarkers
showed no correlation with fluid retention during treatment,
but associations between biomarkers and neutrophil (sE-
selectin) as well as platelet reconstitution (adhesion molecule
profile) could be detected.
5. Conclusion
We describe an association between preconditioning en-
dothelial cell biomarkers and organ involvement in acute
GVHD. Based on these observations our hypothesis is that
differences in immunocompetent cell trafficking caused by
differences in endothelial cell phenotype between target
organs are important in the pathogenesis and thereby also for
the clinical presentation of acute GVHD.
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